
    
      This retrospective cases series is a non-randomized, open-label, single-center investigation
      (Retina Clinic, São Paulo, Brazil) approved by the Institutional Review Board of Hospital
      Oftalmológico de Sorocaba/SP, and adhered to the tenets of the Declaration of Helsinki. Were
      included patients older than 18 years, treated between April 2014 and July 2015, diagnosed
      with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who
      underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg
      (Avastin; Genentech, South San Francisco, CA) and intravitreal implant of dexamethasone 0.7mg
      (Ozurdex; Allergan, Inc, Irvine, CA).
    
  